Q4 EPS Estimates for Globus Medical Reduced by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Roth Capital cut their Q4 2025 earnings per share (EPS) estimates for Globus Medical in a research report issued to clients and investors on Wednesday, November 6th. Roth Capital analyst J. Wittes now expects that the medical device company will post earnings per share of $0.91 for the quarter, down from their previous forecast of $0.92. The consensus estimate for Globus Medical’s current full-year earnings is $2.84 per share.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.18. The firm had revenue of $625.71 million during the quarter, compared to analysts’ expectations of $604.69 million. Globus Medical had a return on equity of 8.70% and a net margin of 1.82%. The company’s revenue for the quarter was up 63.1% compared to the same quarter last year. During the same period last year, the business posted $0.57 earnings per share.

Several other brokerages have also recently weighed in on GMED. Bank of America lifted their price target on Globus Medical from $55.00 to $80.00 and gave the company an “underperform” rating in a research report on Wednesday. Needham & Company LLC reiterated a “hold” rating on shares of Globus Medical in a research report on Wednesday. BTIG Research lifted their price target on Globus Medical from $77.00 to $78.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Piper Sandler lifted their price target on Globus Medical from $80.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Truist Financial raised their price objective on Globus Medical from $78.00 to $79.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $87.09.

Globus Medical Trading Up 9.4 %

Shares of GMED stock opened at $82.70 on Thursday. The stock has a 50 day moving average of $71.92 and a 200 day moving average of $68.16. The stock has a market cap of $11.20 billion, a P/E ratio of 275.67, a P/E/G ratio of 2.06 and a beta of 1.17. Globus Medical has a twelve month low of $43.38 and a twelve month high of $84.87.

Insider Transactions at Globus Medical

In other news, Director Ann D. Rhoads sold 15,000 shares of Globus Medical stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $70.36, for a total value of $1,055,400.00. Following the sale, the director now directly owns 42,884 shares of the company’s stock, valued at $3,017,318.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Ann D. Rhoads sold 15,000 shares of Globus Medical stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $70.36, for a total value of $1,055,400.00. Following the sale, the director now directly owns 42,884 shares of the company’s stock, valued at $3,017,318.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David D. Davidar sold 30,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $75.04, for a total value of $2,251,200.00. Following the completion of the sale, the director now directly owns 536,275 shares in the company, valued at $40,242,076. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 18.54% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

A number of institutional investors have recently added to or reduced their stakes in GMED. V Square Quantitative Management LLC purchased a new position in Globus Medical during the third quarter worth approximately $27,000. Ashton Thomas Private Wealth LLC purchased a new stake in Globus Medical in the second quarter valued at $33,000. Farther Finance Advisors LLC raised its position in Globus Medical by 230.5% in the third quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock valued at $39,000 after purchasing an additional 385 shares during the period. GAMMA Investing LLC raised its position in Globus Medical by 254.5% in the second quarter. GAMMA Investing LLC now owns 631 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 453 shares during the period. Finally, International Assets Investment Management LLC purchased a new stake in Globus Medical in the second quarter valued at $52,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.